Morgan Stanley Satsuma Pharmaceuticals, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.7 - $1.07 $2,275 - $3,478	-3,251 Reduced 29.07%	7,932 $5,000
Q4 2022 Feb 14, 2023	SELL	$0.61 - $5.06 $129,706 - $1.08 Million	-212,633 Reduced 95.0%	11,183 $10,000
Q3 2022 Nov 14, 2022	SELL	$4.19 - $7.95 $95,850 - $181,864	-22,876 Reduced 9.27%	223,816 $1.34 Million
Q2 2022 Oct 27, 2022	BUY	$2.59 - $4.3 $606,855 - $1.01 Million	234,307 Added 1891.86%	246,692 $1.02 Million
Q2 2022 Aug 15, 2022	BUY	$2.59 - $4.3 $606,855 - $1.01 Million	234,307 Added 1891.86%	246,692 $1.02 Million
Q1 2022 Oct 27, 2022	SELL	$3.78 - $5.32 $885,680 - $1.25 Million	-234,307 Reduced 94.98%	12,385 $47,000
Q1 2022 May 13, 2022	SELL	$3.78 - $5.32 $160,026 - $225,222	-42,335 Reduced 77.37%	12,385 $47,000
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $196,585 - $295,588	-47,370 Reduced 46.4%	54,720 $246,000
Q3 2021 Nov 15, 2021	BUY	$4.54 - $7.17 $463,488 - $731,985	102,090 New	102,090 $475,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.